Shandong Buchang Pharmaceuticals Co Ltd (603858) - Net Assets
Based on the latest financial reports, Shandong Buchang Pharmaceuticals Co Ltd (603858) has net assets worth CN¥10.07 Billion CNY (≈ $1.47 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥19.57 Billion ≈ $2.86 Billion USD) and total liabilities (CN¥9.50 Billion ≈ $1.39 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset allocation strategy of Shandong Buchang Pharmaceuticals Co Ltd to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥10.07 Billion |
| % of Total Assets | 51.47% |
| Annual Growth Rate | 10.12% |
| 5-Year Change | -28.98% |
| 10-Year Change | 35.09% |
| Growth Volatility | 27.62 |
Shandong Buchang Pharmaceuticals Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Shandong Buchang Pharmaceuticals Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Shandong Buchang Pharmaceuticals Co Ltd market cap and net worth.
Annual Net Assets for Shandong Buchang Pharmaceuticals Co Ltd (2011–2024)
The table below shows the annual net assets of Shandong Buchang Pharmaceuticals Co Ltd from 2011 to 2024. Also explore net asset momentum of Shandong Buchang Pharmaceuticals Co Ltd to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥9.81 Billion ≈ $1.44 Billion |
-13.78% |
| 2023-12-31 | CN¥11.38 Billion ≈ $1.66 Billion |
-7.32% |
| 2022-12-31 | CN¥12.28 Billion ≈ $1.80 Billion |
-15.05% |
| 2021-12-31 | CN¥14.45 Billion ≈ $2.11 Billion |
+4.63% |
| 2020-12-31 | CN¥13.81 Billion ≈ $2.02 Billion |
+0.17% |
| 2019-12-31 | CN¥13.79 Billion ≈ $2.02 Billion |
-0.51% |
| 2018-12-31 | CN¥13.86 Billion ≈ $2.03 Billion |
+4.84% |
| 2017-12-31 | CN¥13.22 Billion ≈ $1.93 Billion |
+3.96% |
| 2016-12-31 | CN¥12.71 Billion ≈ $1.86 Billion |
+75.12% |
| 2015-12-31 | CN¥7.26 Billion ≈ $1.06 Billion |
+63.18% |
| 2014-12-31 | CN¥4.45 Billion ≈ $651.08 Million |
+3.86% |
| 2013-12-31 | CN¥4.28 Billion ≈ $626.87 Million |
+6.51% |
| 2012-12-31 | CN¥4.02 Billion ≈ $588.56 Million |
+43.56% |
| 2011-12-31 | CN¥2.80 Billion ≈ $409.96 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shandong Buchang Pharmaceuticals Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 157.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥6.75 Billion | 66.05% |
| Common Stock | CN¥1.11 Billion | 10.83% |
| Other Comprehensive Income | CN¥11.23 Million | 0.11% |
| Other Components | CN¥2.35 Billion | 23.02% |
| Total Equity | CN¥10.22 Billion | 100.00% |
Shandong Buchang Pharmaceuticals Co Ltd Competitors by Market Cap
The table below lists competitors of Shandong Buchang Pharmaceuticals Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
The Andersons Inc
NASDAQ:ANDE
|
$2.28 Billion |
|
Douzone Bizon Co Ltd
KO:012510
|
$2.28 Billion |
|
Cadeler A/S
NYSE:CDLR
|
$2.28 Billion |
|
Shanghai Huafon Aluminium Corp
SHG:601702
|
$2.28 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
$2.28 Billion |
|
Ebos Group Ltd
AU:EBO
|
$2.28 Billion |
|
Y.H. Dimri Construction & Development Ltd
TA:DIMRI
|
$2.28 Billion |
|
Billerud AB
ST:BILL
|
$2.28 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shandong Buchang Pharmaceuticals Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 11,616,993,595 to 10,216,464,921, a change of -1,400,528,674 (-12.1%).
- Net loss of 553,797,934 reduced equity.
- Dividend payments of 272,436,211 reduced retained earnings.
- Share repurchases of 702,339,747 reduced equity.
- Other comprehensive income decreased equity by 605,745.
- Other factors increased equity by 128,650,963.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-553.80 Million | -5.42% |
| Dividends Paid | CN¥272.44 Million | -2.67% |
| Share Repurchases | CN¥702.34 Million | -6.87% |
| Other Comprehensive Income | CN¥-605.75K | -0.01% |
| Other Changes | CN¥128.65 Million | +1.26% |
| Total Change | CN¥- | -12.06% |
Book Value vs Market Value Analysis
This analysis compares Shandong Buchang Pharmaceuticals Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.57x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 6.41x to 1.57x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥2.30 | CN¥14.77 | x |
| 2012-12-31 | CN¥3.67 | CN¥14.77 | x |
| 2013-12-31 | CN¥3.96 | CN¥14.77 | x |
| 2014-12-31 | CN¥4.26 | CN¥14.77 | x |
| 2015-12-31 | CN¥6.92 | CN¥14.77 | x |
| 2016-12-31 | CN¥12.07 | CN¥14.77 | x |
| 2017-12-31 | CN¥11.41 | CN¥14.77 | x |
| 2018-12-31 | CN¥12.03 | CN¥14.77 | x |
| 2019-12-31 | CN¥12.22 | CN¥14.77 | x |
| 2020-12-31 | CN¥12.40 | CN¥14.77 | x |
| 2021-12-31 | CN¥13.04 | CN¥14.77 | x |
| 2022-12-31 | CN¥11.18 | CN¥14.77 | x |
| 2023-12-31 | CN¥10.50 | CN¥14.77 | x |
| 2024-12-31 | CN¥9.43 | CN¥14.77 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shandong Buchang Pharmaceuticals Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.42%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5.03%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 1.89x
- Recent ROE (-5.42%) is below the historical average (17.83%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 46.72% | 20.92% | 1.32x | 1.69x | CN¥965.27 Million |
| 2012 | 32.85% | 17.78% | 1.24x | 1.49x | CN¥870.45 Million |
| 2013 | 28.51% | 13.60% | 1.24x | 1.69x | CN¥758.69 Million |
| 2014 | 30.08% | 12.81% | 1.14x | 2.07x | CN¥883.53 Million |
| 2015 | 49.45% | 30.34% | 0.74x | 2.20x | CN¥2.82 Billion |
| 2016 | 14.04% | 14.36% | 0.66x | 1.48x | CN¥508.76 Million |
| 2017 | 12.46% | 11.81% | 0.72x | 1.46x | CN¥323.73 Million |
| 2018 | 13.75% | 13.82% | 0.68x | 1.46x | CN¥514.95 Million |
| 2019 | 14.27% | 13.65% | 0.67x | 1.55x | CN¥582.16 Million |
| 2020 | 13.57% | 11.63% | 0.70x | 1.67x | CN¥489.43 Million |
| 2021 | 8.94% | 8.18% | 0.66x | 1.66x | CN¥-153.23 Million |
| 2022 | -12.37% | -10.23% | 0.68x | 1.78x | CN¥-2.77 Billion |
| 2023 | 2.75% | 2.41% | 0.63x | 1.80x | CN¥-842.73 Million |
| 2024 | -5.42% | -5.03% | 0.57x | 1.89x | CN¥-1.58 Billion |
Industry Comparison
This section compares Shandong Buchang Pharmaceuticals Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,877,324,223
- Average return on equity (ROE) among peers: 8.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shandong Buchang Pharmaceuticals Co Ltd (603858) | CN¥10.07 Billion | 46.72% | 0.94x | $2.28 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.78 Billion | 1.33% | 4.40x | $589.07 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.56 Billion | 7.90% | 1.45x | $422.95 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $2.46 Billion | 15.95% | 0.27x | $4.31 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.17 Billion | 10.59% | 0.88x | $2.30 Billion |
| Wedge Industrial Co Ltd (000534) | $1.41 Billion | 5.42% | 0.68x | $1.73 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $32.60 Million | 12.25% | 0.82x | $13.40 Billion |
| Hainan Haiyao Co Ltd (000566) | $2.54 Billion | 7.70% | 0.92x | $945.43 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $380.02 Million | 7.98% | 0.67x | $320.64 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $3.92 Billion | 4.44% | 2.20x | $1.01 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $23.53 Billion | 7.26% | 0.16x | $3.11 Billion |
About Shandong Buchang Pharmaceuticals Co Ltd
Shandong Buchang Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of medicines in China. It offers medicines to treat cardiac and cerebral vascular, urinary and digestive, respiratory, gynecological, and other diseases, as well as diabetes. The company was founded in 1993 and is based in Heze, China.